But instead she can now add some shadily-timed trading of Mylan stock to her growing list of “Things That Suck For Me Right Now.” Heather Bresch, the CEO at the center of EpiPen’s 471% price hike, sold 100,200 of her shares earlier this …
What a difference a hostile takeover bid can make. Perrigo Co. for months has been publicly trashing Mylan NV and its prospects as part of an effort to fend off a roughly $27 billion hostile bid from the Dutch company. But the concerns …
Mylan N.V. MYL is scheduled to report first-quarter 2017 results on May 10, before the market opens. The company’s performance has been mixed so far, having beaten earnings estimates in three of the trailing four quarters and missing …
PITTSBURGH, Pa. - The generic drugmaker Mylan is buying Abbott Laboratories' generic-drugs business in developed markets for stock valued at about $5.3 billion. Mylan said Monday that the deal will diversify and expand its business …
First, CEO Bresch may have engaged in insider trading when she sold over 100,000 shares of Mylan stock in advance of the latest price increases. As noted in the second link above, the stock price fell drastically after Dr. Rogers' piece was …
Mylan CEO Heather Bresch listens to an aide during a hearing before lying to the House Oversight and Government Reform Committee on September 21, 2016 (Photo by Alex Wong/Getty Images) Mylan, the drug company that makes …
Shareholders of the drugmaker Perrigo have shut the door on a $26-billion hostile takeover bid from Mylan. Mylan said that its cash-and-stock offer failed to garner enough interest from Perrigo shareholders by a Friday morning deadline to …
Mylan’s stock price surged after their price increase strategy, going from as low as $14.84 per share in 2007, when it first bought EpiPens, to as high as $49.09 on Monday. Attention given to the rising price of the pens has prompted calls …
That amounts to $222.12 a share based on Mylan's closing price Thursday — 10 percent above the price of Perrigo's stock the same day. Perrigo had rejected an earlier proposal of $205 a share, saying it didn't reflect the value of its …
The Teva cash and stock proposal provides Mylan stockholders with a substantial premium and immediate cash value, as well as significant potential for future value creation through participation in a financially and commercially stronger …